{"analyses":[{"ciLowerLimit":"0.22","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.65","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.67","paramType":"Hazard Ratio (HR)","paramValue":"0.77","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Median RFS not reached The 95% confidence intervals were not calculable because an insufficient number of participants reached the event at the final time point for assessment.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median RFS not reached The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment.","groupId":"OG001","lowerLimit":"38.9","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"89"}],"units":"Participants"}],"description":"RFS was defined as time from end of 2 cycles of blinatumomab to relapse or to death without documentation of relapse. Patients without events were censored at the date of last disease assessment.\n\nRelapse/Persistent Disease\n\nPersistent disease/Relapse following complete remission (CR)/complete remission incomplete (CRi) is defined as:\n\n* Reappearance or persistence of blasts in the blood\n* Presence of \\> 5% blasts, not attributable to another cause (e.g., bone marrow regeneration).\n* In the case of isolated CNS relapse such as a positive cytospin examination of CSF, please consult with Study Chair. Perform bone marrow biopsy (if not already done) to confirm presence or lack of medullary relapse.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients who are MRD positive (MRD+) at randomization/registration and then convert to MRD negative (MRD-) after 2 cycles of blinatumomab or consolidation chemotherapy.\n\n.","id":"OG000","title":"MRD+ Then Convert to MRD-"},{"description":"Patients who are MRD negative (MRD-) at randomization/registration and then remain MRD negative (MRD-) after 2 cycles of blinatumomab or consolidation chemotherapy.\n\n.","id":"OG001","title":"MRD- Then Remain MRD-"}],"paramType":"MEDIAN","populationDescription":"Patients with MRD data at the end of 2 cycles of blinatumomab were included in the analysis.","reportingStatus":"POSTED","timeFrame":"Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 5 years","title":"RFS Among of Those Who Are MRD+ at Randomization and Then Convert to MRD- After 2 Cycles of Blinatumomab to Those Patients Who Are MRD- at Randomization and Remain MRD- After 2 Cycles of Blinatumomab or Consolidation Chemotherapy","type":"SECONDARY","unitOfMeasure":"months"}